Trial Profile
Safety of imatinib and nilotinib in patients with chronic myeloid leukaemia: A single center prospective study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Sep 2017
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- 27 Sep 2017 New trial record
- 30 Aug 2017 Results presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology